Atavistik Bio is a biotechnology company accelerating the discovery and development of transformative precision allosteric therapeutics to address serious unmet patient needs, with a focus on oncology. Since its inception, Atavistik Bio has rapidly established an emerging pipeline of allosteric therapeutics with the potential to achieve superior efficacy and tolerability profiles by leveraging the power of allostery. ATV-1601, a selective allosteric inhibitor for solid tumors, is anticipated to enter the clinic in early 2025. Atavistik Bio is led by an experienced team of drug hunters with a proven track record of developing marketed small molecule therapies and supported by top-tier investors, including The Column Group, Nextech Invest, and Lux Capital.
Company Details
- Employees
- 38
- Founded
- -
- Address
- Cambridge, Ma 02139, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://atavistikbio.com/
- HQ
- Cambridge, MA
Atavistik Bio Questions
Atavistik Bio's website is https://atavistikbio.com/
Atavistik Bio's LinkedIn profile is https://www.linkedin.com/company/atavistik-bio
Atavistik Bio has
38 employees.
View email and phone details for 38
employees at Atavistik Bio.
Atavistik Bio's industry is
Biotechnology Research
Atavistik Bio's top competitors are
Passkey Therapeutics,
Triana Biomedicines,
Mural Oncology,
Fulcrum Therapeutics,
Enveda,
Moma Therapeutics,
Entrada Therapeutics,
Judo Bio,
Incendia Therapeutics,
Full Circles Therapeutics Inc..
Atavistik Bio's categories are Biotechnology Research
Atavistik Bio's founding year is 2021
